Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Conference Call February 14, 2023 1:00 PM ET
Company Representatives
Jan D'Alvise - President, Chief Executive Officer
Brian Ford - Chief Financial Officer
Pierre Lemieux - Chief Operating and Scientific Officer, Co-Founder
Prashant Kohli - Chief Commercial Officer
Robert Blum - Lytham Partners
Conference Call Participants
Leland Gershell - Oppenheimer
Oren Livnat - H.C. Wainwright
Operator
Good day, and welcome to the Acasti Pharma Reports Third Quarter of Fiscal Year 2023 Financial Results and Business Update Call. All participants will be in listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded.
I would now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead.
Robert Blum
All right, thank you very much Jason. Welcome to Acasti Pharma's third quarter fiscal 2023 conference call. On the call with us this afternoon is Jan D'Alvise, President and CEO; Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating and Scientific Officer, and Acasti Co-Founder; and Prashant Kohli, Chief Commercial Officer.
Following management's prepared remarks, there will be a Q-&-A session. Should any questions remain after the call, please contact me at 602-889-9700. I'd also like to remind everyone that statements on this conference call that are not statements of historical or current facts constitute forward-looking information within the meaning of Canadian Securities Laws and forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and the Securities and Exchange Act of 1934.
Such forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results to be materially different from those expressed or implied by such forward-looking statements.
In addition to statements which explicitly describe such risks and uncertainties, listeners are urged to consider statement labeled with terms belief, expects, intends, anticipates, potential, should, may, will, plans, continue, targeted or other similar expressions to be uncertain and forward-looking. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call.
Forward-looking statements during this conference call may include, but are not limited to the success and timing of regulatory submissions of Acasti planned, pre-clinical and clinical trials, regulatory requirements or developments in the outcome of meetings with the FDA, changes to clinical trial designs and regulatory pathways, legislative, regulatory, political, and economic developments and actual costs associated with Acasti's pre-clinical and clinical trials as compared to management’s current expectations.